US Medical Innovations

What US Medical Innovations does

US Medical Innovations (USMI) is a privately-held biomedical device company developing plasma-based surgical systems and cancer treatment technologies. Founded in 2009 and operating as a wholly-owned subsidiary of US Patent Innovations, LLC, the company is headquartered in Takoma Park, Maryland with 11-50 employees. Its portfolio is anchored by proprietary Cold Atmospheric Plasma (CAP) and Hybrid Plasma technologies, including the FDA 510(k)-cleared Canady Helios Cold Plasma (CHCP) Ablation System, the Canady Plasma XL-1000 SMART Electrosurgical Generator, the Canady Hybrid Plasma Scalpel, the Canady Plasma Probes, the FDA-approved Canady Flex RoboWrist for open and laparoscopic procedures, and the Canady Robotic AI Surgical System debuted in January 2024. The CHCP system delivers non-thermal (26-30°C) plasma via a non-contact jet, creating reactive oxygen and nitrogen species alongside a Plasma Treatment Electromagnetic Field (PTEF) that induces irreversible electroporation and apoptosis selectively in cancer cells at surgical margins while sparing normal tissue.

USMI's clinical evidence base centers on the first FDA Phase I IDE trial (#G190165) for cold atmospheric plasma in cancer, which enrolled 20 patients between March 2020 and April 2021 across Rush University Medical Center and Sheba Medical Center and demonstrated a 69% overall response rate for clean-margin patients and 100% for microscopic-positive-margin patients, with 80% local recurrence-free survival at 26 months for the latter cohort. Results were published in MDPI's Cancers journal in August 2023, with additional peer-reviewed research in Nature Scientific Reports, Applied Sciences, International Journal of Molecular Sciences, and Clinical Plasma Medicine covering 32 cancer cell lines. The underlying molecular mechanism, histone mRNA oxidation driving DNA damage response and cell death, is patented (U.S. Patent No. 9999462) and was discovered by the Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS), the company's integrated research arm founded and led by USMI's CEO Dr. Jerome Canady.

USMI operates a capital equipment hardware sales model, selling devices directly to hospital procurement departments and surgical centers through an enterprise field sales motion. Revenue is generated primarily through one-time purchases of electrosurgical generators and surgical instruments, with potential recurring revenue from consumables such as probes and replacement instruments. Its primary customer segment is surgical oncology, targeting hospitals performing solid tumor resections where microscopic positive margins drive local regional recurrence; secondary segments include minimally invasive surgery and general/orthopedic surgery. Distribution is direct domestically, with established pre-existing international presence across the Middle East, Europe, and Asia for the Canady Flex RoboWrist prior to its US FDA approval. As of its September 2022 funding round, USMI announced plans for a 2023 IPO, though the company remains private.

Name

US Medical Innovations

Legal name

US Medical Innovations, LLC

Website

https://usmedinnovations.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

US Medical Innovations is a privately-held biomedical device company developing plasma-based surgical and cancer treatment systems. It sells FDA-cleared Cold Atmospheric Plasma and electrosurgical devices to hospitals and surgical centers, targeting surgical oncology as its primary segment.

Ownership category

akta.pro rank

Product category

Surgical Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser) (HLAHADAC)

Keywords

• Electrosurgical generators
• Cold plasma therapy
• Surgical robotics instruments
• Soft tissue ablation
• Oncology medical devices

Headquarters

HQ city

Lakeland

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: Sale of capital equipment including the Canady Plasma XL-1000 SMART Electrosurgical Generator to hospitals and surgical centers. One-time hardware purchase model.
2. Surgical Instruments and Consumables: Sale of surgical instruments including Canady Hybrid Plasma Scalpels, Canady Plasma Probes, and other procedural consumables. Potential recurring revenue through instrument replacement and probe sales.
3. Cold Plasma Treatment Technology: Revenue from Canady Helios Cold Plasma Generator systems for cancer treatment applications in surgical settings. The $10.2M private placement funding was allocated to ramp up manufacturing of the XL-1000 and development of CHCP and robotic delivery system.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

US Medical Innovations develops and manufactures plasma-based biomedical devices for surgical oncology and electrosurgery, including the FDA 510(k)-cleared Canady Helios Cold Plasma (CHCP) Ablation System for soft tissue ablation during surgery, the Canady Plasma XL-1000 SMART Electrosurgical Generator, the Canady Hybrid Plasma Scalpel and Probes, the FDA-approved Canady Flex RoboWrist articulating surgical instrument, and the Canady Robotic AI Surgical System. Its core technology delivers non-thermal Cold Atmospheric Plasma that selectively targets residual microscopic cancer cells at surgical margins without damaging healthy tissue. The company sells this capital equipment and reusable instruments primarily to hospitals, surgical centers, and surgical oncology teams.

Product overview

US Medical Innovations is a biomedical device company specializing in plasma-based surgical and cancer treatment technologies. The company offers a portfolio of medical devices centered on proprietary Cold Atmospheric Plasma (CAP) and Hybrid Plasma technologies. The core product line includes the Canady Helios Cold Plasma (CHCP) System for cancer cell ablation at surgical margins, the Canady Hybrid Plasma Scalpel for simultaneous cutting and coagulation, and the Canady Plasma XL-1000 SMART Electrosurgical Generator powering these instruments. The portfolio is expanding into surgical robotics with the Canady Flex RoboWrist (FDA-approved hand-held articulating instrument) and the Canady Robotic AI Surgical System. All products are developed by USMI in partnership with the Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS).

Differentiator

Problem solved

Functional benefit

Brands

• Canady Helios Cold Plasma: Non-thermal cold atmospheric plasma system for ablation of soft tissue and treatment of cancer at surgical margins.
• Canady Hybrid Plasma
• Canady Plasma XL 1000 SMART Electrosurgical Generator
• Canady Flex RoboWrist

Products and services

• Canady Helios Cold Plasma (CHCP) System Non-thermal Cold Atmospheric Plasma system that delivers a room-temperature plasma beam creating reactive oxygen/nitrogen species (ROS/RNS) and a Plasma Treatment Electromagnetic Field (PTEF) to selectively target and destroy cancer cells at surgical margins without damaging normal tissue. FDA 510(k) cleared for ablation of soft tissue during surgery and intended for hospitals and surgical oncology teams performing solid tumor resections.
• Canady Plasma XL-1000 SMART Electrosurgical Generator High-definition touchscreen electrosurgical generator featuring Canady Hybrid Plasma Technology, built-in surgical applications, and multiple safety and security features. Supports electrosurgery for traditional procedures such as hip and knee replacements, and powers the Canady Hybrid Plasma Scalpel, Probes, and Flex RoboWrist. Sold to hospitals and surgical centers as capital equipment.
• Canady Hybrid Plasma Scalpel Surgical instrument that combines monopolar electrical charge with plasma gas to create a plasma beam that simultaneously cuts and coagulates biological tissue. Used in general surgery, oncology, orthopedic, plastic, and neurological procedures, and is intended for hospital surgical departments.
• Canady Plasma Probes Plasma-based surgical probes that are part of the Canady Hybrid Plasma system, used for plasma-based surgical procedures including laparoscopic, endoscopic, and open surgeries. Sold to hospitals and surgical centers.
• Canady Flex RoboWrist FDA-approved fully articulating motorized 5mm hand-held surgical instrument offering 3 degrees of freedom and 360° rotation, available with hook, scissors, needle driver, and dissector end effectors. Includes connector for XL-1000 electrosurgical generator enabling mono scissors or hook electrosurgery, is autoclavable up to 50 times with no disposables required, and is intended for open and laparoscopic procedures.
• Canady Robotic AI Surgical System Advanced robotic surgical system incorporating AI technology for surgical procedures, debuted at the First Global Surgical Oncology Summit in January 2024. Developed jointly by JCRI-ABTS and USMI.

Quantifiable outcome

• 69% overall response rate for R0 (clean margin) patients; 100% for R0-MPM (microscopic positive margin) patients at 26 months
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS)coreStrategic or Co-development PartnerJCRI-ABTS is the research arm of USMI, conducting the underlying science for cold atmospheric plasma technology. The institute discovered and patented the mechanism by which CHCP induces cell death through histone mRNA oxidation. Research laboratory developed standard treatment dosages for 32 cancer cell lines. Molecular biological studies for clinical trials performed at JCRI-ABTS.
• Rush University Medical CentercoreStrategic or Co-development PartnerPrimary US clinical trial site for Phase I FDA IDE study of Canady Helios Cold Plasma. 75% of 20 enrolled patients treated at this site. Dr. Steven Gitelis (Chief of Surgery) and Dr. Keith Millikan served as principal investigators.
• Sheba Medical CentercoreStrategic or Co-development PartnerInternational clinical trial site in Tel HaShomer, Israel for Phase I study. 25% of 20 enrolled patients treated at this site. Dr. Aviram Nissan served as principal investigator. Contributed to international validation of CHCP treatment.
• US Patent Innovations, LLC (Parent Company)coreOthersUSMI is a wholly-owned subsidiary of US Patent Innovations, LLC. US Patent Innovations provides IP ownership and corporate structure. USMI is described as a Biomedical and Life Science subsidiary of US Patent Innovations.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Medtronic: Global medical device leader with the Hugo robotic-assisted surgery platform and a broad electrosurgical and energy-device portfolio. Competes with USMI across both the energy-based surgical device category and the robotic surgery category, with vastly larger commercial reach.
• Intuitive Surgical: Incumbent leader in robotic-assisted surgery with the da Vinci platform, controlling a large share of US surgical robotics. Comparable as the dominant standard USMI's Canady Robotic AI Surgical System and Canady Flex RoboWrist must compete against or partner with in minimally invasive oncology surgery.
• Boston Scientific: Diversified medical device company with a meaningful electrosurgery and energy portfolio alongside interventional oncology products. Comparable as a broad incumbent offering overlapping energy-based surgical and ablation solutions to the same hospital customer base.
• Integra LifeSciences: Specialty surgical device company with offerings in neurosurgery, ENT, and surgical instruments including electrosurgical generators. Comparable as an incumbent supplier of OR equipment and surgical instruments to the same hospital procurement channels USMI targets.
• Smith+Nephew: Global medical device player with surgical instruments, advanced energy devices, and robotic-assisted surgery platforms (CORI). Comparable as a broad incumbent competing in arthroscopy, orthopedics, and minimally invasive surgical instrumentation where USMI's Canady Flex RoboWrist is positioned.
• Stryker: Major surgical device and orthopedic company with the Mako robotic surgery system. Comparable as a broad incumbent USMI competes against in surgical robotics and in the orthopedic oncology segment where USMI has surgeon adoption (e.g., Dr. Anthony Carter).
• Johnson & Johnson (Ethicon): Ethicon offers a deep portfolio of electrosurgical, advanced energy, and surgical robotics products (including the Ottava robotic platform). A direct competitor in laparoscopic and open surgical instruments where Canady Flex RoboWrist and the Hybrid Plasma Scalpel operate.

Emerging players

• AngioDynamics: Medical technology company with a portfolio of tumor ablation and interventional oncology devices. Comparable to USMI as a focused player developing energy-based ablation solutions for cancer treatment, though AngioDynamics emphasizes percutaneous ablation while USMI focuses on intraoperative margin treatment.

Direct peers

• Apyx Medical: Commercializes the Renuvion (formerly J-Plasma) helium-based plasma/RF surgical system for cutting, coagulation, and tissue contraction. Directly competes with USMI's Canady Hybrid Plasma and CHCP platforms in the plasma-electrosurgery category, targeting surgeons and hospitals with overlapping value propositions.
• Plasma Surgical: Developer of the PlasmaJet system, a neutral plasma energy device for surgical coagulation and tissue effects. Closely comparable to USMI's plasma-based surgical devices in mechanism (plasma-mediated tissue effects) and target user (surgical oncology / general surgery).

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/USMI_LLC
• Facebookfacebook.com/6300980
• LinkedInlinkedin.com/company/us-medical-innovations-llc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about US Medical Innovations